logo
Twitter
Discord
Email
logo
Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc.

NASDAQ•NRIX
CEO: Dr. Arthur T. Sands M.D., Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2020-07-24
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
Contact Information
1700 Owens Street, Suite 205, San Francisco, CA, 94158, United States
415-660-5320
www.nurixtx.com
Market Cap
$1.47B
P/E (TTM)
-6.6
42.1
Dividend Yield
--
52W High
$22.50
52W Low
$8.18
52W Range
76%
Rank55Top 68.5%
3.0
F-Score
Modified Piotroski Analysis
Based on 7-year fundamentals
Weak • 3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2018-2024

Financial Dashboard

Q3 2025 Data

Revenue

$7.89M-37.29%
4-Quarter Trend

EPS

-$1.03+53.73%
4-Quarter Trend

FCF

-$60.10M+34.97%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Revenue Jumps 70.8% Total revenue reached $70.4M for nine months ended August 31, 2025, up 70.8% from $41.3M, boosted by $30.0M license revenue.
R&D Spending Accelerates Research and development expenses increased $79.5M to $233.9M for nine months, reflecting accelerated clinical trial enrollment and headcount growth.
Collaboration Revenue Decreases Collaboration revenue fell $0.9M to $40.4M for nine months, primarily due to concluding the initial research term with Sanofi.
Cash Position $428.8 Million Cash, cash equivalents, and marketable securities totaled $428.8M as of August 31, 2025, following significant operating cash usage.

Risk Factors

Continued Operating Losses Expected Expect incurring losses over several years; accumulated deficit reached $925.0M as of August 31, 2025, requiring substantial future funding.
Early Stage Clinical Development Lead drug candidates (NX-5948, NX-2127, NX-1607) are in early clinical stages with high inherent risk of failure or significant delays.
Need Substantial Additional Funding Operations require substantial additional capital to fund clinical trials through commercialization; failure to raise capital limits development programs.
Reliance on Third-Party Manufacturing Dependence on CMOs for drug substance and product increases risk of supply disruption, cost overruns, or quality issues impacting timelines.

Outlook

Phase 2 Trial Planned 2025 Plan to initiate Phase 2 clinical trial for bexobrutideg (NX-5948) in 2025, following ongoing Phase 1 dose-escalation study completion.
Liquidity Runway Exceeds Twelve Months Current cash resources are deemed sufficient to fund operating activities for at least 12 months following the reporting date.
Advance DEL-AI Platform Capabilities Strategy focuses on expanding DEL-AI platform capabilities and advancing pipeline candidates through preclinical and clinical development.
Retain US Co-Development Options Retain options for profit sharing and co-promotion in US for multiple drug candidates under existing major collaboration agreements.

Peer Comparison

Revenue (TTM)

Iovance Biotherapeutics, Inc.IOVA
$250.43M
+175.6%
Day One Biopharmaceuticals, Inc.DAWN
$133.67M
+30.4%
Nurix Therapeutics, Inc.NRIX
$83.69M
+48.3%

Gross Margin (Latest Quarter)

Day One Biopharmaceuticals, Inc.DAWN
88.7%
-9.6pp
UroGen Pharma Ltd.URGN
85.3%
-4.5pp
Nurix Therapeutics, Inc.NRIX
36.7%
+377.4pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
TERN$4.05B-44.9-27.4%0.4%
OLMA$2.27B-18.9-41.5%0.4%
NRIX$1.47B-6.6-53.6%10.8%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-15.9%
Growth Under Pressure
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Jan 27, 2026
|
EPS:-$0.85
|
Revenue:$13.41M
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Aug 31, 2025|Filed: Oct 9, 2025|
    Revenue: $7.89M-37.3%
    |
    EPS: $-1.03+53.7%
    Miss

  • Form 10-Q - Q2 2025

    Period End: May 31, 2025|Filed: Jul 9, 2025|
    Revenue: $44.06M+264.3%
    |
    EPS: $-0.52-26.8%
    Beat

  • Form 10-Q - Q1 2025

    Period End: Feb 28, 2025|Filed: Apr 8, 2025|
    Revenue: $18.45M+11.3%
    |
    EPS: $-0.67-11.8%
    Beat

  • Form 10-K - FY 2024

    Period End: Nov 30, 2024|Filed: Jan 28, 2025|
    Revenue: $54.55M-29.1%
    |
    EPS: $-2.88-8.7%
    Miss

  • Form 10-Q - Q3 2024

    Period End: Aug 31, 2024|Filed: Oct 11, 2024|
    Revenue: $12.59M-31.8%
    |
    EPS: $-0.67-1.5%
    Beat

  • Form 10-Q - Q2 2024

    Period End: May 31, 2024|Filed: Jul 11, 2024|
    Revenue: $12.09M-60.6%
    |
    EPS: $-0.71+77.5%
    Miss

  • Form 10-Q - Q1 2024

    Period End: Feb 29, 2024|Filed: Apr 10, 2024|
    Revenue: $16.59M+30.7%
    |
    EPS: $-0.76+16.9%
    Meet

  • Form 10-K - FY 2023

    Period End: Nov 30, 2023|Filed: Feb 15, 2024|
    Revenue: $76.99M+99.3%
    |
    EPS: $-2.65+28.6%
    Miss